Dr Bruce Campbell
Bruce Campbell joined IQur as non-executive Director in 2005. He has more than 45 years of drug development experience and has developed many drugs in a wide range of indications which are now on the market. Formerly R&D Director at Servier (UK), Senior VP of International Development at Neurocrine Biosciences, Inc (US), Chief Scientific Officer at IP2IPO ( IPGroup), Founder, Chairman and Head of Development for Proximagen Ltd. before it was sold to Upsher Smith ( $300M). He currently acts as a consultant to various pharmaceutical companies . In addition, he has also been a director and European Chairman of the Drug Information Association, and a member of the European ICH Safety Working Party. He is a visiting Professor in Pharmacology at King’s College, London and written more than 100 papers involving all aspects of drug development .
Professor William Rosenberg
Founder, Chief Scientific Officer and Chief Executive Officer
Professor Rosenberg founded the company in 2003, and was appointed CEO in 2007.
Brenda Reynolds is currently CEO of Calchan Holdings Ltd, a Biotech company specialising in medicines for pain and inflammation. She was previously a founder and COO of both Convergence Pharmaceuticals, acquired by Biogen in early 2015, and PowderMed Ltd, acquired by Pfizer in 2006. She is also an NED and independent advisor to a number of life science companies. Earlier in her career Brenda held senior roles within the Pharmaceutical Industry specialising in Project and change management. She is Toxicologist by training and is also a Chartered Director and Fellow of the IOD.
Dr John Tite
John joined the iQur Board in 2009 and is currently works as an independent consultant. He was previously founding CEO and Board Director of Bicycle Therapeutics. Prior to this, he was Vice President and Head of Discovery Biology for the GSK Biopharm CEDD where hewas responsible for biology support for biopharm discovery and development. John has a degree in Zoology and PhD in Immunology followed by post-doctoral training at Yale University Medical School. He has been involved in the discovery and development of therapeutic antibodies and vaccines for over 25 years and was the Chairman of the Board for the Edward Jenner Institute for Vaccine Research. John is a frequent contributor to MRC and CR-UK review panels and is currently a member of the MRC-Technology Scientific Advisory Board and Chair of the CR-UKBiotherapeutics Expert Review Panel.